In this podcast, Josep Bassaganya-Riera, DVM, PhD, Chairman, CEO, and Founder of Landos Biopharma, an emerging biotech company, discusses their important work in the development of new therapeutics to combat autoimmune disease.
Dr. Bassaganya-Riera has been part of major research funded by prestigious grants from institutions, such as the National Institutes of Health and the United States Department of Agriculture (USDA). Dr. Bassaganya-Riera is Principal Investigator and Director for the Modeling Immunity to Enteric Pathogens (MIEP) project that studies the immunoregulatory mechanisms underlying infections with select gut pathogens through the use and application of mathematical systems to mucosal immunology.
Dr. Bassaganya-Riera talks about Landos Biopharma, the emerging biotech company that is creating a stir in the autoimmune disease research and therapeutic development field. Dr. Bassaganya-Riera explains some of the needs that are not currently being met by Crohn's disease treatment, and he talks about colitis—a chronic digestive disease identified by inflammation, often severe, of the colon’s innermost lining.
Dr. Bassaganya-Riera talks about Landos Biopharma’s completion of phase one clinical trials. And the research doctor provides information on various other diseases of the gastrointestinal tract. He explains their leading clinical asset—BT-11—which is a new, oral, locally-acting molecule that specifically targets the Lanthionine Synthetase C-Like 2 (LANCL2) pathway in the GI tract for the treatment of inflammatory bowel disease.
Dr. Bassaganya-Riera has published over 100 scientific papers, secured 9 patents, and he received the 2018 Research Excellence Award from the Biocomplexity Institute of Virginia Tech.